Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 65,000 Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Intellia Therapeutics, purchasing 65,000 shares valued at approximately $462,000.
• Institutional investors own 88.77% of Intellia Therapeutics, with notable increases in holdings by several firms during the previous quarter.
• Analysts have a consensus rating of "Moderate Buy" for Intellia Therapeutics, with an average target price set at $33.37, taking into account varying opinions including target price adjustments from different firms.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 65,000 shares of the company's stock, valued at approximately $462,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.06% of Intellia Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. GF Fund Management CO. LTD. acquired a new position in shares of Intellia Therapeutics during the 4th quarter valued at $25,000. Sterling Capital Management LLC lifted its holdings in Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after buying an additional 2,867 shares in the last quarter. Resona Asset Management Co. Ltd. acquired a new position in Intellia Therapeutics in the 4th quarter worth $43,000. Virtus ETF Advisers LLC lifted its holdings in Intellia Therapeutics by 47.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company's stock worth $61,000 after buying an additional 1,692 shares in the last quarter. Finally, 49 Wealth Management LLC acquired a new position in Intellia Therapeutics in the 1st quarter worth $74,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Up 0.2%

Intellia Therapeutics stock traded up $0.02 during mid-day trading on Thursday, hitting $11.39. 3,121,750 shares of the stock were exchanged, compared to its average volume of 4,037,955. The firm's fifty day simple moving average is $10.39 and its two-hundred day simple moving average is $9.49. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -2.18 and a beta of 2.31. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $24.16.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. Intellia Therapeutics had a negative net margin of 1,154.10% and a negative return on equity of 56.06%. The business's revenue was down 42.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.12) EPS. As a group, analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Citigroup dropped their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Wolfe Research raised shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective for the company in a research report on Monday, April 21st. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 16th. Chardan Capital reissued a "buy" rating and set a $68.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 9th. Finally, Canaccord Genuity Group reduced their target price on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research note on Tuesday, June 3rd. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $33.37.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the transaction, the executive vice president directly owned 106,062 shares in the company, valued at $1,486,989.24. This trade represents a 6.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 12,534 shares of company stock valued at $153,837 in the last quarter. 3.10% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.